

SUPPLEMENTARY MATERIAL





Figure S1. HR-ESI-MS of compound 1







Figure S2. ¹H-NMR spectrum of compound 1







Figure S3. ^{13}C -NMR spectrum of compound 1







Figure S4. HSQC spectrum of compound 1






Figure S5. HMBC spectrum of compound 1





Figure S6. HR-ESI-MS of compound 2







Figure S7. ¹H-NMR spectrum of compound 2






Figure S8. ¹³C-NMR spectrum of compound 2




Figure S9. HSQC spectrum of compound 2




Figure S10. HMBC spectrum of compound 2




Figure S11. COSY spectrum of compound 2




Figure S12. Dose response curve assessing the effect of compound 1-3 and capecitabine on cell viability in PC-3 cells. PC-3 cells were treated with compound 1-3 and capecitabine for 48 h, and the cell viability was determined using MTS assay kit (mean \pm S.E., $n = 3$).




Figure S13. Effect of Ani-D2 on cell viability in HaCaT cells. Cells were treated with Ani-D2 at the indicated concentrations for 72 h, and cell viability was determined using MTS assay kit (mean \pm S.E., $n = 3$).